Top Markets
Coin of the day
Jyong Biotech Ltd. Ordinary Shares Jyong Biotech Ltd. Ordinary Shares

Jyong Biotech Ltd. Ordinary Shares

MENS
Rank in Stocks #19255
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the... Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Share Price
$2.22
Last synced: 2026-08-25
Market Cap
$168.64M
Change (1 day)
-0.09%
Change (1 year)
-95.58%
Country
TW
Trade Jyong Biotech Ltd. Ordinary Shares (MENS)

Category

Operating Margin for Jyong Biotech Ltd. Ordinary Shares (MENS)
Operating Margin as of 2026 TTM: 0.00%
According to Jyong Biotech Ltd. Ordinary Shares latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Jyong Biotech Ltd. Ordinary Shares from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
28.81% -
NL
-149.01% -
US
25.72% -
AU
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.